Clinical trials: Functional Test
Early Onset Alzheimer Disease
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)
The purpose of this study is to evaluate the efficacy of NKO™ softgels in reducing decline of global cognitive function as measured by the Neuropsychological Test Battery (NTB), in patients diagnosed with early stage Alzheimer's…
- Trial name
- MNEMOSYNE (NCT00867828)
- Testing
- Neptune Krill Oil, Fish Oil
- Where
- 14 sites in Canada
- Volunteers
- 175 people
- Sponsor
- NeuroBioPharm Inc.
TLC in Patients With and Without Respiratory System Disease
Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)
A comparative study to test the efficacy of a novel device - the MiniBoxPFT, in measuring TLC (total lung capacity) compared to TLC measured by standard body plethysmography using the ZAN 500.
- Trial name
- NCT01952431
- Testing
- Total Lung Capacity (TLC) testing
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PulmOne Advanced Medical Devices, Ltd.
Monogenic Disorders
Development of In Vitro Functional Assays From Primary Cells of Patients With Monogenic Diseases
The objective of this project is to build a collection of biological samples consisting of fibroblasts and primary keratinocytes from patients with orphan monogenic diseases and to use these cells in the customization of…
- Trial name
- OPERANDO (NCT03763864)
- Testing
- Skin Biopsy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Apteeus
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Idiopathic Pulmonary Fibrosis
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study.
- Trial name
- NCT06335303
- Testing
- BI 1819479
- Where
- 163 sites in United States, Argentina and 26 more
- Volunteers
- 322 people
- Sponsor
- Boehringer Ingelheim